Partner 3 Trial Results
Data from the Partner 3 trial shows that transcatheter aortic valve replacement (TAVR) devices have similar outcomes to surgically implanted valves (SAVR) in terms of device durability.
According to the seven-year data, there is no statistically significant difference in outcomes such as mortality and morbidity between TAVR and SAVR.
Stakeholders of all stripes have wondered whether transcatheter aortic valve replacement devices could match their surgically implanted cousins for device durability.
The results suggest that patients, physicians, payers, and regulators can be confident in the durability of TAVR devices.
Author's summary: TAVR matches SAVR in durability.
More News
- 'What a player': Adams praises Kroupi's mentality - “his ceiling is really high”
- Sixers Bell Ringer: Sixers storm back to shock Wizards in OT and remain unbeaten
- 'Surreal' for Jones to see Cherries' journey in nine years at club
- Why investors are betting big on AI-powered health care
- International Court of Justice’s ruling on climate change affirms states’ obligations to human and planetary health
- Windows File Explorer Previews are Vulnerable to NTLM Hash Leakage – How to Stay Safe - Make Tech Easier
- Who's enrolled in Sioux Falls' public schools
- Obituaries – Week of Oct. 27, 2025 - The Observer
- Pre-school praised for 'working hard to improve' with exemplary Ofsted report